Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026)

Zoetis' (ZTS) quarterly Non-Current Deferred Tax Liability came in at $130.0 million in Q1 2026, down 19.25% year-on-year from $161.0 million in Q1 2025, and down 5.11% on a QoQ basis from $137.0 million in Q4 2025.

Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $130.0 million in Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 19.25% year-over-year to $130.0 million in Q1 2026; TTM through Mar 2026 was $130.0 million, a 19.25% decrease from a year earlier, with the FY2025 full-year figure at $137.0 million, down 17.96% from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 stood at $130.0 million, down from $137.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for ZTS reached as high as $287.0 million in Q1 2022 and fell as low as $121.0 million in Q2 2023.
  • Historically, Non-Current Deferred Tax Liability has averaged $170.5 million across 5 years, with a median of $156.0 million in 2025.
  • Across the five-year window, Non-Current Deferred Tax Liability plunged 55.84% in 2023 and jumped 44.63% in 2024, its largest moves.
  • Year by year, Non-Current Deferred Tax Liability stood at $142.0 million in 2022, then climbed by 2.82% to $146.0 million in 2023, then climbed by 14.38% to $167.0 million in 2024, then fell by 17.96% to $137.0 million in 2025, then retreated by 5.11% to $130.0 million in 2026.
  • Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $130.0 million in Q1 2026, $137.0 million in Q4 2025, and $147.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 88.07 Bn 86.20 Bn -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 130.00 Mn
Mar 31, 2026 130.00 Mn
Dec 31, 2025 137.00 Mn
Dec 31, 2025 137.00 Mn
Sep 30, 2025 147.00 Mn
Sep 30, 2025 147.00 Mn
Jun 30, 2025 156.00 Mn
Jun 30, 2025 156.00 Mn
Mar 31, 2025 161.00 Mn
Mar 31, 2025 161.00 Mn
Dec 31, 2024 167.00 Mn
Dec 31, 2024 167.00 Mn
Sep 30, 2024 172.00 Mn
Sep 30, 2024 172.00 Mn
Jun 30, 2024 175.00 Mn
Jun 30, 2024 175.00 Mn
Mar 31, 2024 136.00 Mn
Mar 31, 2024 136.00 Mn
Dec 31, 2023 146.00 Mn
Dec 31, 2023 146.00 Mn